Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

REYKJAVIK, Iceland and LONDON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Commission has approved Mynzepli^® as a biosimilar to Eylea^® (aflibercept), in a pre-filled syringe and vial.